FDA issued an emergency use authorization (EUA) for casirivimab and imdevimab (Regeneron Pharmaceuticals) to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years or older weighing about 88 pounds with positive results of direct SARS-CoV-2 viral testing and who are at high risk for pr

On Saturday, FDA issued an emergency use authorization (EUA) for a combination monoclonal antibody treatment—casirivimab and imdevimab (Regeneron Pharmaceuticals)—to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years and older weighing 88 pounds with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

Pfizer announced that it plans to ask FDA on Friday for emergency use authorization of its COVID-19 vaccine. Pfizer and partner BioNTech reported this week the two-dose vaccine was 95% effective and well-tolerated.

Older adults responded favorably to AstraZeneca's COVID-19 vaccine, according to Phase II peer-reviewed results reported in The Lancet.

Pfizer and BioNTech reported Wednesday their experimental COVID-19 vaccine was 95% effective in the final results of a key study. According to the companies, Pfizer intends to seek FDA authorization for the vaccine within days.